Menopausal Hormone Therapy and Non-Hormonal Options Shortages in Australia – Update 23 June 2021
There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:
Oral MHT
Duavive – supply due to be resolved by end January 2022
Progynova 2mg – supply due to be resolved by end of April 2022
Femonston Conti – supply shortage expected between 25 June and 9 July
Transdermal MHT
Estradot 100 – supply due to be resolved by 31 August
Estradot 75 – supply due to be resolved by 31 August
Estradot 50 – supply due to be resolved by 1 July
Estradot 37.5 – supply due to be resolved by 31 August
Estradot 25 – supply due to be resolved by 1 July
Estalis Conti 50/140 – supply resolved
Estalis Conti 50/250 – supply resolved
Estalis Sequi 50/140 – supply resolved
Estalis Sequi 50/250 – supply resolved
Estraderm MX 50 – supply resolved
Estraderm MX 100 - supply resolved
Non-Hormonal Options
There is also an expected shortage of supply of non-hormonal treatment options:
Gabapentin-APOTEX 100mg – supply shortage expected between 20 August- 15 October
Gabapentin 300mg- supply shortage expected between 18 June- 16 July
APX-Gabapentin 300mg- supply shortage expected between 16 July- 6 August
Gabapentin-APOTEX 300mg – to be discontinued from 18 July
Combined oral contraceptive pill
There is also an expected shortage of combined oral contraceptive pill:
Qliara – supply due to be resolved by 1 June 2022
Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.